23andMe creates new therapeutics group and apoints Genentech's Richard Scheller to lead
Privately-held genomics and biotech company 23andMe has created a new therapeutics group, and appointed Richard Scheller to lead it.
Dr Scheller retired in December 2014 after 14 years at Genentech, a subsidy of Roche (ROG: SIX), where he was executive vice president of research and early development.
Anne Wojcicki, chief executive and co-founder of 23andMe, said: “With Dr Scheller joining the team, we are putting significant resources into translating genetic information into the discovery and development of new therapies for our customers and the world. This is a major step forward to realizing our mission to help people benefit from the human genome.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze